AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03355027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80mg
Description: Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
Study NCT04648176 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moses technology
Description: Using Holmium laser with Moses technology or conventional one
Study NCT02597660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive exercise program
Description: Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
Study NCT02597660 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Patellar tendon biopsy
Description: Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
Study NCT02597660 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patellar tendon biopsy
Description: Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
Study NCT02209571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood markers
Description: Routine venous blood sampling
Study NCT02209571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood markers
Description: Routine venous blood sampling
Study NCT00076817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP205)
Description: Canarypox virus vector vaccine
Study NCT00076817 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV (vCP205)
Description: Canarypox virus vector vaccine placbo
Study NCT04648176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moses technology
Description: Using Holmium laser with Moses technology or conventional one
Study NCT02813460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation H3 (ALS-008176)
Description: 60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
Study NCT02367846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive Vaginal Ring (CVR)
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
Study NCT01083108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Description: The surgical group will be studied before and 6 days after bariatric surgery.
Study NCT01083108 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caloric Restriction
Description: The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
Study NCT02426814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use.
Study NCT02426814 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use.
Study NCT02426814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for asthma adherence
Description: Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
Study NCT00991952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00571402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-focused therapy for adolescents
Description: FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
Study NCT00571402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced care
Description: Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
Study NCT00040846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given IV
Study NCT00040846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT03406676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
Study NCT04695678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 nasal/pharyngeal swab
Description: each study participant receives a nasal/pharyngeal swab
Study NCT00153842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene (targretin)
Description: Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg
Study NCT00153842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene (targretin)
Description: Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg
Study NCT01756755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMX-20R Hemoperfusion
Description: Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
Study NCT01805050 — intervention group
Intervention type: PROCEDURE
Intervention: Arthroscopically repair of the anterior shoulder instability
Description: Arthroscopically repair of the anterior shoulder instability
Study NCT00040846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00040846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic HSCT
Study NCT03740490 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Smart-T + NRT
Description: Smart-Treatment App and Nicotine Replacement Therapy
Study NCT03740490 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide + NRT
Description: NCI QuitGuide Treatment App and Nicotine Replacement Therapy
Study NCT00040846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation
Study NCT00040846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study NCT00040846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine
Description: Bupivacaine 12.5 mg will be administered in the subarachnoid space.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal bupivacaine
Description: Bupivacaine 12.5 mg will be administered in the subarachnoid space.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl
Description: Fentanyl 15 µg will be administered in the subarachnoid space.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal fentanyl
Description: Fentanyl 15 µg will be administered in the subarachnoid space.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Description: Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean delivery
Description: Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients' abdomen.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: IV ketorolac 30 mg/8 h starting at the end of surgery.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV ketorolac 30 mg/8 h starting at the end of surgery.
Study NCT03742440 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GrafixPL PRIME
Description: GrafixPL PRIME
Study NCT00998777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder Strengthening
Description: The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
Study NCT04745273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG (Kemoset 4mg)
Description: Ondansetron 4mg (iv) will administer to participants
Study NCT04745273 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salin solution
Description: Salin solution 2ml (iv) will administer to participants
Study NCT05023824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-blocker or 5-ARI withdrawal
Description: Withdrawal of either alpha-blocker or 5-ARI
Study NCT05023824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of alpha-blocker and 5-ARI
Description: Maintenance of alpha-blocker and 5-ARI
Study NCT02003274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clamp-Mixed Meal
Description: Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
Study NCT02003274 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IVGTT-Mixed Meal Arm
Description: Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal.
Study NCT01931709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG PET
Study NCT01931709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo FDG PET
Study NCT01931709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT01931709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01028690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
Study NCT01028690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00040456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mg Pidolate
Description: Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
Study NCT00040456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
Study NCT01640327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIVf)
Description: A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
Study NCT01569243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messages
Description: * Participants will receive diabetic medical care as usual.~* Participants will be given an ActiHealth pedometer to measure daily activity.~* In addition, they will be enrolled to receive the study text messages.
Study NCT01569243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: * Participants will receive diabetic medical care as usual.~* In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity).
Study NCT04074239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video triage
Description: The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
Study NCT01792570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV + DRV/r
Description: Switch to dual HAART
Study NCT01792570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continue the PI/r-containing HAART.
Description: Continue the on-going triple drug HAART.
Study NCT03740815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Description: Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
Study NCT03740815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Description: Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
Study NCT03740815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous sedation
Description: Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
Study NCT03256890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB-BP Intervention
Description: MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
Study NCT03256890 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Control
Description: Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance.
Study NCT01107379 — intervention group
Intervention type: DEVICE
Intervention: Relieva Balloon Sinuplasty System
Description: Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
Study NCT03655002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Oral paracetamol 1 gm/8 h starting 4 h after surgery.
Study NCT02691572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Oral paracetamol 1 gm/8 h starting 4 h after surgery.
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fentanyl patient-controlled analgesia
Description: Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
Study NCT02256722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL
Study NCT02691572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl patient-controlled analgesia
Description: Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
Study NCT02256722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Study NCT02256722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Study NCT02256722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Study NCT02256722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Study NCT01900340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline infusion and intraduodenal administration of saline via feeding tube